{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:44:40Z","timestamp":1793943880023,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematopoietic chimerism after allogeneic bone marrow transplantation may establish a state of donor\u00a0antigen-specific tolerance. However, current allotransplantation protocols involve genotoxic conditioning which has harmful side-effects and predisposes to infection and cancer. Here we describe a non-genotoxic conditioning protocol for fully MHC-mismatched bone marrow allotransplantation in mice involving transient immunosuppression and selective depletion of recipient hematopoietic stem cells with a CD117-antibody-drug-conjugate (ADC). This protocol resulted in multilineage, high level (up to 50%), durable, donor-derived hematopoietic chimerism after transplantation of 20 million total bone marrow cells, compared with \u2264\u00a02.1% hematopoietic chimerism from 50 million total bone marrow cells without conditioning. Moreover, long-term survival of bone marrow donor-type but not third party\u00a0skin allografts is achieved in CD117-ADC-conditioned chimeric mice without chronic immunosuppression. The only observed adverse event is transient elevation of liver enzymes in the first week after conditioning. These results provide proof-of-principle for CD117-ADC as a non\u2212genotoxic, highly-targeted conditioning agent in allotransplantation and tolerance protocols.<\/jats:p>","DOI":"10.1038\/s41467-018-08202-w","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T11:04:47Z","timestamp":1549451087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation"],"prefix":"10.1038","volume":"10","author":[{"given":"Zhanzhuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Czechowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Scheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-1293","authenticated-orcid":false,"given":"Derrick J.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"8202_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1126\/science.1149726","volume":"318","author":"A Czechowicz","year":"2007","unstructured":"Czechowicz, A., Kraft, D., Weissman, I. L. & Bhattacharya, D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318, 1296\u20131299 (2007).","journal-title":"Science"},{"key":"8202_CR2","doi-asserted-by":"publisher","first-page":"351ra105","DOI":"10.1126\/scitranslmed.aae0501","volume":"8","author":"A Chhabra","year":"2016","unstructured":"Xue, X. et al. Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice.\u00a0Blood\u00a0\n                           116, 5419\u20135422 (2010).","journal-title":"Sci. Transl. Med."},{"key":"8202_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","volume":"34","author":"R Palchaudhuri","year":"2016","unstructured":"\u200bYokoi, T. et al. Non-myeloablative preconditioning with ACK2 (anti-c-kit antibody) is efficient in bone marrow transplantation for murine models of mucopolysaccharidosis type II.\u00a0Mol. Genet. Metab.\u00a0119, 232\u2013238 (2016).","journal-title":"Nat. Biotechnol."},{"key":"8202_CR4","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","volume":"116","author":"X Xue","year":"2010","unstructured":"Chandrakasan, S. et al. KIT blockade is sufficient for donor hematopoietic stem cell engraftment in Fanconi anemia mice.\u00a0Blood\u00a0\n                           129, 1048\u20131052 (2017).","journal-title":"Blood"},{"key":"8202_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ymgme.2016.08.003","volume":"119","author":"T Yokoi","year":"2016","unstructured":"\u200bChhabra, A. et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.\u00a0Sci. Transl. Med.\u00a08, 351ra105 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"8202_CR6","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1182\/blood-2015-12-689083","volume":"129","author":"S Chandrakasan","year":"2017","unstructured":"Palchaudhuri, R. et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.\u00a0Nat. Biotechnol.\u00a034, 738\u2013745 (2016).","journal-title":"Blood"},{"key":"8202_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0092-8674(90)90280-R","volume":"63","author":"ON Witte","year":"1990","unstructured":"Witte, O. N. Steel locus defines new multipotent growth factor. Cell 63, 5\u20136 (1990).","journal-title":"Cell"},{"key":"8202_CR8","doi-asserted-by":"publisher","unstructured":"Czechowicz, A. et al. \u00a0Selective HSC ablation using anti CD117 immunotoxins enables safe and effective hematopoietic stem cell transplantation with preservation of immunity. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-018-08201-x\u00a0(2019).","DOI":"10.1038\/s41467-018-08201-x"},{"key":"8202_CR9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","volume":"130","author":"CD Fitzhugh","year":"2017","unstructured":"Fitzhugh, C. D. et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood 130, 1946\u20131948 (2017).","journal-title":"Blood"},{"key":"8202_CR10","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/jpids\/piy015","volume":"7","author":"JA Connelly","year":"2018","unstructured":"Connelly, J. A., Marsh, R., Parikh, S. & Talano, J. A. Allogeneic hematopoietic cell transplantation for chronic granulomatous disease: controversies and state of the art. J. Pediatr. Infect. Dis. Soc. 7, S31\u2013S39 (2018).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"8202_CR11","doi-asserted-by":"publisher","first-page":"10122","DOI":"10.1073\/pnas.0400084101","volume":"101","author":"L Graca","year":"2004","unstructured":"Graca, L. et al. Donor-specific transplantation tolerance: the paradoxical behavior of CD4\u2009+\u2009CD25\u2009+\u2009T cells. Proc. Natl Acad. Sci. USA 101, 10122\u201310126 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8202_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.trim.2015.07.003","volume":"33","author":"Z Li","year":"2015","unstructured":"Li, Z., Xu, X., Weiss, I. D., Jacobson, O. & Murphy, P. M. Pre-treatment of allogeneic bone marrow recipients with the CXCR4 antagonist AMD3100 transiently enhances hematopoietic chimerism without promoting donor-specific skin allograft tolerance. Transpl. Immunol. 33, 125\u2013129 (2015).","journal-title":"Transpl. Immunol."},{"key":"8202_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep22143","volume":"6","author":"Z Li","year":"2016","unstructured":"Li, Z., Xu, X., Feng, X. & Murphy, P. M. The macrophage-depleting agent clodronate promotes durable hematopoietic chimerism and donor-specific skin allograft tolerance in mice. Sci. Rep. 6, 22143 (2016).","journal-title":"Sci. Rep."},{"key":"8202_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2015.01.014","volume":"160","author":"DH McDermott","year":"2015","unstructured":"McDermott, D. H. et al. Chromothriptic cure of WHIM syndrome. Cell 160, 686\u2013699 (2015).","journal-title":"Cell"},{"key":"8202_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","volume":"7","author":"MC Walters","year":"2001","unstructured":"Walters, M. C. et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 7, 665\u2013673 (2001).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"8202_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bmt.1702151","volume":"25","author":"M Andreani","year":"2000","unstructured":"Andreani, M. et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25, 401\u2013404 (2000).","journal-title":"Bone Marrow Transplant."},{"key":"8202_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0022-3476(98)70201-X","volume":"133","author":"N Guffon","year":"1998","unstructured":"Guffon, N., Souillet, G., Maire, I., Straczek, J. & Guibaud, P. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J. Pediatr. 133, 119\u2013125 (1998).","journal-title":"J. Pediatr."},{"key":"8202_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/307168a0","volume":"307","author":"ST Ildstad","year":"1984","unstructured":"Ildstad, S. T. & Sachs, D. H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307, 168\u2013170 (1984).","journal-title":"Nature"},{"key":"8202_CR19","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1056\/NEJMc1213779","volume":"368","author":"T Kawai","year":"2013","unstructured":"Kawai, T., Sachs, D. H., Sykes, M. & Cosimi, A. B. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 368, 1850\u20131852 (2013).","journal-title":"N. Engl. J. Med."},{"key":"8202_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/323164a0","volume":"323","author":"SP Cobbold","year":"1986","unstructured":"Cobbold, S. P., Martin, G., Qin, S. & Waldmann, H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 323, 164\u2013166 (1986).","journal-title":"Nature"},{"key":"8202_CR21","doi-asserted-by":"crossref","unstructured":"Czechowicz, A. et al. \u00a0Targeted clearance of human hematopoietic stem cell niches via inhibition of SCF signaling using monoclonal antibody SR-1. Blood. 116, 74 (2010).","DOI":"10.1182\/blood.V116.21.74.74"},{"key":"8202_CR22","unstructured":"Agarwal, R. et al. First evidence that an antibody against CD117 can enable hematopoietic stem cell engraftment in patients undergoing transplantation. LBA 8, American Society for Blood and Marrow Transplantation Tandem Meeting, Salt Lake City, Utah. https:\/\/bmt.confex.com\/tandem\/2018\/meetingapp.cgi\/Paper\/11778 (2018)."},{"key":"8202_CR23","doi-asserted-by":"crossref","unstructured":"Pearse, B. R. et al. CD117-Amanitin antibody drug conjugates effectively deplete human and non-human Primate HSCs: proof of concept as a targeted strategy for conditioning patients for bone marrow transplant. Blood\u00a0132, 3314 (2018).","DOI":"10.1182\/blood-2018-99-114881"},{"key":"8202_CR24","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1111\/j.1600-6143.2008.02419.x","volume":"8","author":"Z Li","year":"2008","unstructured":"Li, Z. et al. CD8\u2009+\u2009T-Cell depletion and rapamycin synergize with combined coreceptor\/stimulation blockade to induce robust limb allograft tolerance in mice. Am. J. Transplant. 8, 2527\u20132536 (2008).","journal-title":"Am. J. Transplant."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08202-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T20:02:01Z","timestamp":1671220921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08202-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8202"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-08202-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.L., A.C., D.J.R., and P.M.M. are listed as inventors on a patent application disclosing CD117 antibody-drug-conjugates as a conditioning agent in allotransplantation filed with the US Patent and Trademark Office. Additional disclosures for A.C.: inventor, US patent applications (US 12\/447,634; US 14\/536,319; US 15\/025,222; and US 15\/148,837); Third Rock Ventures: Consultancy; GV: Salary;\u00a0Global Blood Therapeutics: Equity Ownership, Consultancy; Editas Medicines: Equity Ownership, Patents & Royalties; Magenta Therapeutics: Equity Ownership, Patents & Royalties; Forty Seven Inc: Patents & Royalties, Beam Therapeutics: Equity Ownership, Consultancy. Additional disclosures for D.J.R.: Inventor, US patent application (US 14\/509,787; US 15\/148,837); Moderna Therapeutics: Equity Ownership, Patents & Royalties;\u00a0Intellia Therapeutics: Equity Ownership, Patents & Royalties, Consultant; Vor Biopharma, Equity Ownership, Consultant; Magenta Therapeutics: Equity Ownership, Patents & Royalties; Stelexis Therapeutics: Equity Ownership, Consultant, Director; Convelo Therapeutics: Equity Ownership, Consultant, Director. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"616"}}